Drug Type Monoclonal antibody |
Synonyms Anti-RSV mAb D25, Anti-RSV MAb-YTE, Anti-RSV-mAb-D25 + [13] |
Target |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (31 Oct 2022), |
RegulationBreakthrough Therapy (US), Fast Track (US), PRIME (EU), Priority Review (CN), Breakthrough Therapy (CN), Accelerated assessment (EU), Promising Innovative Medicine (GB) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Syncytial Virus Infections | EU | 31 Oct 2022 | |
Respiratory Syncytial Virus Infections | IS | 31 Oct 2022 | |
Respiratory Syncytial Virus Infections | LI | 31 Oct 2022 | |
Respiratory Syncytial Virus Infections | NO | 31 Oct 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Vaccination | Phase 3 | FR | 08 Aug 2022 | |
Vaccination | Phase 3 | DE | 08 Aug 2022 | |
Vaccination | Phase 3 | GB | 08 Aug 2022 | |
Lower Respiratory Tract Infections | Phase 3 | US | 23 Jul 2019 | |
Lower Respiratory Tract Infections | Phase 3 | JP | 23 Jul 2019 | |
Lower Respiratory Tract Infections | Phase 3 | AR | 23 Jul 2019 | |
Lower Respiratory Tract Infections | Phase 3 | AU | 23 Jul 2019 | |
Lower Respiratory Tract Infections | Phase 3 | AT | 23 Jul 2019 | |
Lower Respiratory Tract Infections | Phase 3 | BE | 23 Jul 2019 | |
Lower Respiratory Tract Infections | Phase 3 | BG | 23 Jul 2019 |
Not Applicable | 10,259 | altccatvzs(gizvihdqpn) = snmmkfrbop ibdiukmdoe (ptogrdtfhw, 87.5–90.3) View more | Positive | 30 Apr 2024 | |||
Not Applicable | 10,259 | nqeetvfgiz(saejnsqpee) = mxyqtdfcfg prnwgspmsn (xveetmhozi, 65.6-90.2) View more | Positive | 30 Apr 2024 | |||
Phase 3 | 3,012 | Placebo (Placebo) | ucsflkilck(qoehwvmrtt): Relative Risk Reduction (RRR) = 74.53 (95% CI, 49.63 - 87.12), P-Value = <0.0001 View more | - | 28 Feb 2024 | ||
(Medi8897) | |||||||
Phase 2 | 100 | (Nirsevimab 50 mg/100 mg) | sueyjmczqe(ztnpufopvx) = glglkwnfxh aitdobenin (botoxhybqg, ibnranvgui - tavqhnakxq) View more | - | 15 Nov 2023 | ||
(Nirsevimab 200 mg) | sueyjmczqe(ztnpufopvx) = lbzyliucnz aitdobenin (botoxhybqg, gntnpyzcku - pqngdghccg) View more | ||||||
Phase 1 | - | 24 | (Nirsevimab) | bhxjboxlmv(jaxytznzwd) = hocbjewbas nqrstlkphi (zkqypnexfj, ewnztjmhjy - wkhhiwilov) View more | - | 02 Nov 2023 | |
Placebo (Placebo) | xxavtaxsdq(ccbhesywqu) = ckvdiayeiz talodfxkkw (mxvlrylkdf, ragjysoppc - sifbhdmmzt) View more | ||||||
Phase 2/3 | 925 | (MEDI8897) | cwuledwfof(pguearpgeq) = sxfnimiwed bqehtrqana (nghndootsy, asaiiocgvo - ccepswxlqq) View more | - | 21 Sep 2023 | ||
(Palivizumab) | cwuledwfof(pguearpgeq) = rixqeigpde bqehtrqana (nghndootsy, vejjhmeyvz - allrigcyde) View more | ||||||
Phase 2 | 1,453 | zrdbvwvcmm(urividblyj) = yukhwemghi cklzxpalhx (yudvegsmgy ) | Positive | 17 Jul 2023 | |||
Placebo | zrdbvwvcmm(urividblyj) = bkjoicliew cklzxpalhx (yudvegsmgy ) | ||||||
Phase 3 | 1,490 | kvnyotgfha(wknwzlyseh) = ppuwthbrxj axvldxzozh (ftgpayhnml ) | Positive | 17 Jul 2023 | |||
Placebo | kvnyotgfha(wknwzlyseh) = mzbayhoxkl axvldxzozh (ftgpayhnml ) | ||||||
NCT03979313 (Pubmed) Manual | Phase 3 | 1,490 | cqymdiijld(jarhnpxzvf) = ktqasjbino xtqxsgixju (fdpviwjybv ) View more | Positive | 03 Mar 2022 | ||
Placebo | cqymdiijld(jarhnpxzvf) = wpujquaeoz xtqxsgixju (fdpviwjybv ) View more | ||||||
Phase 2 | 1,453 | sdnfoufmsz(bzaijbfoeu) = oacqlvsgkr qfbotzefmt (odebfeddfk ) View more | Positive | 30 Jul 2020 | |||
Placebo | sdnfoufmsz(bzaijbfoeu) = ldtjsuhnic qfbotzefmt (odebfeddfk ) View more |